VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) saw unusually-strong trading volume on Thursday. 13,165 shares traded hands during trading, an increase of 61% from the average daily volume of 8,153 shares. The stock last traded at $244.8160 and had previously closed at $244.91.
VanEck Biotech ETF Stock Performance
The firm’s 50 day moving average is $244.76 and its 200 day moving average is $210.54.
Institutional Investors Weigh In On VanEck Biotech ETF
Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new position in VanEck Biotech ETF during the third quarter valued at $24,952,000. Nwam LLC purchased a new stake in shares of VanEck Biotech ETF in the second quarter worth $18,614,000. Quantitative Investment Management LLC purchased a new stake in shares of VanEck Biotech ETF in the second quarter worth $7,589,000. Proficio Capital Partners LLC bought a new position in shares of VanEck Biotech ETF during the second quarter valued at $5,183,000. Finally, Bank of America Corp DE increased its holdings in shares of VanEck Biotech ETF by 44.3% during the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after acquiring an additional 20,375 shares in the last quarter. Institutional investors own 32.05% of the company’s stock.
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Recommended Stories
- Five stocks we like better than VanEck Biotech ETF
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
